We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CV2CoV

News List

Second-Generation mRNA COVID-19 Vaccine Candidate, CV2CoV, Demonstrates Improved Immune Response and Protection in Preclinical Study drugs
August 20, 2021
CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), and GSK today announced the publication of preclinical data investigating immune responses.
Second-generation COVID-19 vaccine candidate, CV2CoV, demonstrates high immunogenicity against virus variants in preclinical study worldpharmanews
May 19, 2021
CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), announced together with its collaboration partner GSK, first preclinical data in a rat model, showing that ...
GSK, CureVac’s next-gen COVID-19 jab generates positive preclinical data pharmatimes
May 17, 2021
GlaxoSmithKline (GSK) and CureVac’s second generation COVID-19 vaccine, CV2CoV, has generated positive preclinical data, the companies announced May 13.